S1616
|
SWOG
|
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1619
|
SWOG
|
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1701
|
SWOG
|
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1702
|
SWOG
|
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1703
|
SWOG
|
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S1706
|
SWOG
|
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1712
|
SWOG
|
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1714
|
SWOG
|
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S1800A
|
SWOG
|
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1800D
|
SWOG
|
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|